Stay updated on Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial
Sign up to get notified when there's something new on the Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial page.

Latest updates to the Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial page
- Check5 days agoNo Change Detected
- Check12 days agoChange DetectedRevision v3.5.2 was added to the history and revision v3.5.0 was removed.SummaryDifference0.1%

- Check19 days agoNo Change Detected
- Check34 days agoChange DetectedAdded Revision: v3.5.0 to the history and removed Revision: v3.4.3.SummaryDifference0.1%

- Check48 days agoChange DetectedNew revision entry v3.4.3 is added and v3.4.2 is removed from the study record history.SummaryDifference0.1%

- Check77 days agoChange DetectedRevision: v3.4.2 was added to the history. Notices about government funding and operating status were removed.SummaryDifference0.8%

- Check84 days agoChange DetectedA site-wide funding-status notice was added and the record history shows Revision v3.4.1, replacing Revision v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.8%

- Check91 days agoChange DetectedUI updates include a new Show glossary option and explanations of the color-coded change highlights (green for additions and red for deletions) with a new revision tag (v3.4.0) visible on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

Stay in the know with updates to Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Venetoclax and Lintuzumab-Ac225 in AML Patients Clinical Trial page.